PMID: 8587272Dec 1, 1995Paper

Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression

Kidney International. Supplement
S Katznelson, J A Kobashigawa

Abstract

Hyperlipidemia has been associated with the development of transplant coronary vasculopathy (TCV) in heart transplant recipients and chronic rejection in kidney transplant recipients. HMG-CoA reductase inhibitors (HMGCoARIs) are effective in treating post-transplant hyperlipidemia, but their effects on patient and graft outcome remain unclear. In a prospective randomized trial investigating pravastatin (PVS) use early after heart transplantation, we observed that PVS treated patients had a decreased incidence of clinically severe acute rejection episodes resulting in a significant improvement in one year survival (94% vs. 78% in the control group, P = 0.02), and decreases in both the incidence and progression of TCV. This observation was validated in a prospective randomized study of kidney transplant recipients where we found that PVS reduced the incidence of acute rejection episodes (25% vs. 58% in the control group, P = 0.01). In both the heart and kidney transplant recipients, taking PVS, we noted decreases in natural killer cell (NKC) cytotoxicity. In vitro studies reveal that: PVS inhibits NKC cytotoxicity; PVS acts synergistically with cyclosporine to inhibit cytotoxic lymphocyte activity; and, other HMGCoARIs inhibit T-...Continue Reading

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Related Papers

Transplant Infectious Disease : an Official Journal of the Transplantation Society
N BabelP Reinke
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
Markus RichterHans Georg Olbrich
© 2021 Meta ULC. All rights reserved